The currently licensed quadrivalent MenACWY-CRM conjugate vaccine presentation consists of two vials (lyophilised MenA and liquid MenCWY) to be reconstituted before injection. A new fully liquid formulation in a single vial has been developed to further improve the vaccine presentation. Since the MenA structure is subject to hydrolytic degradation, this study was conducted to compare the immunogenicity and safety of the investigational MenACWY-CRM liquid vaccine with the licensed vaccine.
In this multicentre, randomised, controlled, observer-blind, phase 2b study, 979 healthy adults were administered a single dose of MenACWY-CRM liquid presentation or the currently licensed MenACWY-CRM vaccine. It showed that Immune responses against each serogroup were similar between the two vaccine groups and was non-inferior for MenA. Both vaccines were well tolerated. No serious adverse events were considered related to vaccination. The immunogenicity, reactogenicity and safety profiles of the two vaccine presentations were similar.
To read more, visit https://pubmed.ncbi.nlm.nih.gov/34635373/